Navigation Links
Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
Date:3/30/2009

ropriate access to IPLEX(TM)."

"We are pleased to be working with Insmed in order to expand access to IPLEX(TM), a drug that has shown significant potential in multiple important therapeutic categories," said John Lagus, Vice President of Business Development for IDIS.

About IPLEX(TM)

IPLEX(TM) was approved in the United States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency (Primary IGFD). IPLEX(TM) rhIGF-I/rhIGFBP-3), is a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3). The drug is also being investigated for various other indications with unmet medical needs.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein development experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

About IDIS

IDIS is the world leader in the development and implementation of Named Patient Programs and has a proven track record of working in strategic partnership with U.S.-based companies to bring new medicines to Europe for the first time. IDIS supports its customers in over 100 countries worldwide, supplying more than 400 different medicines per month and responding to more than half a million requests on a named-patient basis to medical professionals worldwide. Headquartered near central London, IDIS has been a strategic partner to more than 40 pharmaceutical and biotech companies. For more information on IDIS, please visit the website www.idispharma.com or contact John Lagus at '/>"/>

SOURCE Insmed Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
2. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
3. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
4. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
5. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
6. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
7. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
8. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
9. Insmed to Seek Shareholder Approval for Reverse Split
10. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
11. Insmed to Present at Biosimilars 2008 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Philadelphia, PA (PRWEB) July 29, 2014 Philadelphia’s ... to help businesses get their start. The Innovation Center ... and the University City Science Center to help ... its doors on Monday, July 28. , ... corner of 34th and Market Streets, is the new home ...
(Date:7/29/2014)... Seattle, WA (PRWEB) July 29, 2014 ... central IRB services, has been awarded accreditation by ... (IASSC) for its Lean Six Sigma Deployment ... eliminate waste and improve performance. , Quorum’s Lean ... granted the Accredited Deployment Program designation. The designation ...
(Date:7/29/2014)... 2014 Eppendorf Centrifuge 5427 R ... Eppendorf 5427 R is geared towards high-end applications like ... is targeted towards work requiring high sample throughput. Pipette.com ... it compliments their extensive 16, 48, and 64 multichannel ... tubes, PCR tubes, PCR strip tubes, and more. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 EXpressLO LLC, ... lift out specimen preparation solutions, has been granted patent ... for specimen manipulation methods incorporating a unique specimen carrier ... This is the second company patent for EXpressLO LLC ... , These complementary patents extend EXpressLO’s portfolio ...
Breaking Biology Technology:Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2EXpressLO LLC Granted Second U.S. Patent for Innovative Specimen Preparation Methods 2
... Company confirms commercial expression levels of ... status of native Apo AI -, CALGARY, ... biotechnology company developing a portfolio of therapeutic,proteins for ... on July 12, 2007 announcing that the Company ...
... Switzerland, Aug. 21 Roche (SWX: ROG.VX; RO.S),a world-leading ... has extended its offer to acquire all of the,outstanding ... VMSI ),to 5:00 p.m., New York City time on ... to expire at 5:00 p.m., New York City,time, on ...
... Republic, Aug. 21 Medpace,Inc., a leading ... has completed the acquisition of Monax s.r.o., ... Prague, Czech,Republic. This move strengthens the Medpace ... to provide full service clinical research management,within ...
Cached Biology Technology:SemBioSys updates Apo AI development program 2SemBioSys updates Apo AI development program 3SemBioSys updates Apo AI development program 4Roche Extends Tender Offer for Ventana 2Roche Extends Tender Offer for Ventana 3Roche Extends Tender Offer for Ventana 4Medpace Strengthens Presence in Central Europe 2
(Date:7/29/2014)... latest research from the University of Adelaide ... of many preterm children can perform almost as well as ... University,s Robinson Research Institute has found that as ... early life, their cognitive abilities as a teenager can potentially ... results of the study, published in this month,s issue of ...
(Date:7/29/2014)... types of cell, including sperm, bacteria and algae, ... These protrusions, about one-hundredth of a millimetre long, ... fluid. Similar, shorter structures called cilia are found ... perform roles such as moving liquids over the ... versatile: they transport mucus and expel pathogens from ...
(Date:7/28/2014)... additional coral communities showing signs of damage from the Deepwater ... spill in the Gulf of Mexico. The discovery was made ... at Penn State University. A paper describing this work and ... of Mexico will be published during the last week of ... Proceedings of the National Academy of Sciences . , ...
Breaking Biology News(10 mins):Preterm children's brains can catch up years later 2Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2
... neurons communicate. Neurotransmitter molecules released from the presynaptic terminal ... the other, binding to receptors that lead to propagation ... by experts in the field, The Synapse ... complex structures of the pre- and postsynaptic regions, as ...
... eyes sensitive to ultraviolet light, which they may use to ... new Nova Southeastern University study suggests. Tamara Frank, Ph.D., ... Oceanographic Center, who is the principal investigator of the study, ... dark area at the ocean bottom ---- may be using ...
... players on your favourite football team were smaller than their ... defenseless, they would become easy prey for other teams. Similarly, ... organisms vulnerable to their predators, which may pose a serious ... calcium levels the organisms grow slower and cannot build their ...
Cached Biology News:Deep-sea crabs seek food using ultraviolet vision 2Deep-sea crabs seek food using ultraviolet vision 3Changes in water chemistry leave lake critters defenseless 2